首页> 外文期刊>The annals of pharmacotherapy >Intravenous Metoprolol Versus Diltiazem for Rate Control in Noncardiac, Nonthoracic Postoperative Atrial Fibrillation
【24h】

Intravenous Metoprolol Versus Diltiazem for Rate Control in Noncardiac, Nonthoracic Postoperative Atrial Fibrillation

机译:美托洛尔与地尔硫卓静脉注射用于非心源性,非胸腔性术后房颤的速率控制

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Little guidance exists on effective management of postoperative atrial fibrillation (POAF) following noncardiac, nonthoracic (NCNT) surgery. Objectives: The purpose of this study was to identify whether a difference exists between intravenous (IV) metoprolol and diltiazem when used to achieve hemodynamically stable rate control in POAF following NCNT surgery. Methods: This retrospective cohort study examined critically ill adult surgical patients experiencing POAF with rapid ventricular response. Inclusion in the metoprolol or diltiazem treatment group was determined by the initial rate control agent chosen by the prescriber. The primary end point was hemodynamically stable rate control, defined by heart rate (HR) <110 beats/min and blood pressure >90 mm Hg, maintained for 6 hours. Main Results: Patients on metoprolol (n = 66) and diltiazem (n = 55) were similar in age, comorbidities, surgical procedure distribution, acuity of illness, and home rate and rhythm control medications continued during hospitalization; 76% of diltiazem-treated patients achieved hemodynamically stable rate control, compared with only 53% of those receiving metoprolol (P =.005). Safety end points were similar between groups, including the portion requiring a new vasopressor or fluid bolus for hemodynamic support. Conclusions: In NCNT surgery, patients with POAF, IV diltiazem more effectively controlled HR and hemodynamics compared with metoprolol. Results warrant further research into optimal medical management of POAF in this population using these 2 agents.
机译:背景:关于非心脏,非胸腔(NCNT)手术后房颤(POAF)的有效管理的指导很少。目的:本研究的目的是确定静脉注射美托洛尔和地尔硫卓在NCNT手术后用于实现POAF的血流动力学稳定速率控制时是否存在差异。方法:这项回顾性队列研究检查了患有POAF且心室反应迅速的重症成年手术患者。美托洛尔或地尔硫卓治疗组的药敏作用由处方者选择的初始速率控制剂决定。主要终点是血液动力学稳定的速率控制,定义为心率(HR)<110次/分钟,血压> 90毫米汞柱,维持6小时。主要结果:美托洛尔(n = 66)和地尔硫卓(n = 55)的患者在年龄,合并症,手术过程分布,疾病敏锐度以及住院期间继续使用居家率和节律控制药物方面相似。接受地尔硫卓治疗的患者中有76%实现了血液动力学稳定的速率控制,而接受美托洛尔的患者中只有53%(P = .005)。各组之间的安全终点相似,包括需要新的升压药或液体推注以支持血流动力学的部分。结论:在NCNT手术中,与美托洛尔相比,POAF,IV地尔硫卓患者可以更有效地控制HR和血液动力学。结果表明,使用这两种药物可以进一步研究该人群中POAF的最佳医疗管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号